| Name | Title | Contact Details |
|---|---|---|
Ester Falconer |
Chief Technology Officer | Profile |
Sapient enables discovery of circulating biomarkers at unprecedented speed & scale, providing a deeper understanding of human biology to align patients & drug therapies.
Since 1993 Letco Medical has been committed to providing compounding pharmacies complete customer satisfaction by offering the highest quality products, customer service, technical support and the fastest delivery times in the industry. Letco is your partner in compounding. We have an extensive line of chemicals, supplies, equipment, capsules, solutions and bases to support you. Letco Medical was also the first in our industry to offer CSOS ordering for your convenience. We also offer online ordering. We pride ourselves on knowing that satisfaction of a job well done is derived through a combination of hard work, perseverance and a thoughtful approach to do our best for our customers and our company. We communicate honestly and openly to continue to build long lasting, trustworthy relationships with our customers and employees. We thank you for trusting us as partners in your compounding pharmacy. We look forward to working with you.
Clinical stage gene therapy company using a constellation of proprietary AAV vector technologies to develop novel treatments for central nervous system and lysosomal storage diseases
Pioneering GMO and mycotoxin testing technologies and pushing boundaries forward in life science labs, grain markets and the global food supply chain.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.